{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:26:56Z","timestamp":1793287616027,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"ASKA Pharmaceutical Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-025-08750-9","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T02:29:01Z","timestamp":1738808941000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Non-inferiority study to compare the efficacy of relugolix with dienogest for endometriosis-associated pain and usefulness of administering relugolix prior to dienogest (READY study): study protocol for a multicenter randomized controlled study"],"prefix":"10.1186","volume":"26","author":[{"given":"Fuminori","family":"Taniguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2028-881X","authenticated-orcid":false,"given":"Motoko","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Osuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasuku","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Kitawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"8750_CR1","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.fertnstert.2021.11.013","volume":"117","author":"T Harada","year":"2022","unstructured":"Harada T, Osuga Y, Suzuki Y, Fujisawa M, Fukui M, Kitawaki J. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain compared with leuprorelin in Japanese women: a phase 3, randomized, double-blind, noninferiority study. Fertil Steril. 2022;117:583\u201392.","journal-title":"Fertil Steril"},{"key":"8750_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1447-0578.2007.00189.x","volume":"6","author":"M Irahara","year":"2007","unstructured":"Irahara M, Harada T, Momoeda M, Tamaki Y. Hormonal and histological study on irregular genital bleeding in patients with endometriosis during treatment with dienogest, a novel progestational therapeutic agent. Reprod Med Biol. 2007;6:223\u20138.","journal-title":"Reprod Med Biol"},{"key":"8750_CR3","doi-asserted-by":"crossref","unstructured":"Harada T, Taniguchi F, Kitajima M, Kitawaki J, Koga K, Momoeda M, et al. Clinical practice guidelines for endometriosis in Japan (3rd edition). J Obstet Gynaecol Res. 2022;48:2993-3044.","DOI":"10.1111\/jog.15416"},{"key":"8750_CR4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ejogrb.2011.03.012","volume":"157","author":"J Kitawaki","year":"2011","unstructured":"Kitawaki J, Kusuki I, Yamanaka K, Suganuma I. Maintenance therapy with dienogest following gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain. Eur J Obstet Gynecol Reprod Biol. 2011;157:212\u20136.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"8750_CR5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11154-021-09666-w","volume":"23","author":"S Vannuccini","year":"2022","unstructured":"Vannuccini S, Clemenza S, Rossi M, Petraglia F. Hormonal treatments for endometriosis: the endocrine background. Rev Endocr Metab Disord. 2022;23:333\u201355.","journal-title":"Rev Endocr Metab Disord"},{"key":"8750_CR6","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S0015-0282(16)56873-3","volume":"62","author":"T Uemura","year":"1994","unstructured":"Uemura T, Mohri J, Osada H, Suzuki N, Katagiri N, Minaguchi H. Effect of gonadotropin-releasing hormone agonist on the bone mineral density of patients with endometriosis. Fertil Steril. 1994;62:246\u201350.","journal-title":"Fertil Steril"},{"key":"8750_CR7","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.fertnstert.2020.07.055","volume":"115","author":"Y Osuga","year":"2021","unstructured":"Osuga Y, Seki Y, Tanimoto M, Kusumoto T, Kudou K, Terakawa N. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2021;115:397\u2013405.","journal-title":"Fertil Steril"},{"key":"8750_CR8","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12905-021-01393-3","volume":"21","author":"Y Osuga","year":"2021","unstructured":"Osuga Y, Seki Y, Tanimoto M, Kusumoto T, Kudou K, Terakawa N. Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results. BMC Womens Health. 2021;21:250.","journal-title":"BMC Womens Health"},{"key":"8750_CR9","unstructured":"Relumina tablets 40 mg package insert, version 2, 2023. https:\/\/www.info.pmda.go.jp\/go\/pack\/2499013F1027_2_06\/. Accessed 11 Mar 2024 [In Japanese]."},{"key":"8750_CR10","unstructured":"Leuprorelin acetate for injection kit 1.88 mg and 3.75 mg package insert, 2017. https:\/\/www.info.pmda.go.jp\/downfiles\/guide\/ph\/530100_2499407G1038_1_00G.pdf. Accessed 11 Mar 2024 [In Japanese]."},{"key":"8750_CR11","first-page":"129","volume":"36","author":"T Harada","year":"2008","unstructured":"Harada T, Momoeda M, Taketani Y, Aso T, Fukunaga M, Hagino H, et al. A randomized, double-blind, multicenter, controlled trial of dienogest compared to intranasal buserelin acetate in the treatment of endometriosis (phase III). Jpn Pharmacol Ther. 2008;36:129\u201340.","journal-title":"Jpn Pharmacol Ther"},{"key":"8750_CR12","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.","journal-title":"BMJ"},{"key":"8750_CR13","first-page":"221","volume":"102","author":"F Taniguchi","year":"2011","unstructured":"Taniguchi F, Harada T. Diagnosis and treatment for endometriosis. Sanfujinka Chiryo (Obstetrical and Gynecological Therapy). 2011;102:221\u20138.","journal-title":"Sanfujinka Chiryo (Obstetrical and Gynecological Therapy)"},{"key":"8750_CR14","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00404-020-05691-3","volume":"302","author":"R Ozaki","year":"2020","unstructured":"Ozaki R, Kumakiri J, Jinushi M, Ikuma S, Murakami K, Kawasaki Y, et al. Comparison of effect of preoperative dienogest and gonadotropin-releasing hormone agonist administration on laparoscopic cystectomy for ovarian endometriomas. Arch Gynecol Obstet. 2020;302:969\u201376.","journal-title":"Arch Gynecol Obstet"},{"key":"8750_CR15","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/humrep\/dep469","volume":"25","author":"T Strowitzki","year":"2010","unstructured":"Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod. 2010;25:633\u201341.","journal-title":"Hum Reprod"},{"key":"8750_CR16","doi-asserted-by":"publisher","first-page":"11342","DOI":"10.3390\/ijms222111342","volume":"22","author":"J Donnez","year":"2021","unstructured":"Donnez J, Dolmans MM. GnRH antagonists with or without add-back therapy: a new alternative in the management of endometriosis? Int J Mol Sci. 2021;22:11342.","journal-title":"Int J Mol Sci"},{"key":"8750_CR17","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1016\/S0140-6736(22)00622-5","volume":"399","author":"LC Giudice","year":"2022","unstructured":"Giudice LC, As-Sanie S, Arjona Ferreira JC, Becker CM, Abrao MS, Lessey BA, et al. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2). Lancet. 2022;399:2267\u201379.","journal-title":"Lancet"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08750-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-08750-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08750-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T02:29:07Z","timestamp":1738808947000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-08750-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8750"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-08750-9","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]},"assertion":[{"value":"26 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was approved by the Certified Review Board, Tottori University Hospital on 30 January 2024 (version 1.3, approval number: 23C004), and the study is registered in the JRCT ID (registration number: jRCTs061230064, 29 September 2023; ). Any changes to the study protocol, informed consent form (see Additional file 1 for an approved informed consent form), or other study-related documents will need to be approved by the Certified Review Board. After receiving approval, the principal investigator will notify investigators at each study site. This study will be conducted in compliance with the Declaration of Helsinki, Clinical Trials Act (Act No. 16, 2017), and Act on the Protection of Personal Information (Act No. 57, 2003). Investigators will explain the study and obtain written informed consent from all participants prior to the start of any study-related procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FT, YO, TH, and JK received honoraria as a speaker and consultant fee from ASKA Pharmaceutical Co., Ltd. The principal investigators will receive research grant from ASKA Pharmaceutical Co., Ltd. MF is an employee of ASKA Pharmaceutical Co., Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}